NYSE:TEVATeva Pharmaceutical Industries Stock Price, Forecast & News

$12.72

-0.17 (-1.32 %)

(As of 06/4/2020 03:53 PM ET)

Add

Compare

Today's Range

$12.64

Now: $12.72▼

$12.90

50-Day Range

$9.76

MA: $11.17▼

$13.12

52-Week Range

$6.07

Now: $12.72▼

$13.76

Volume5.60 million shs

Average Volume12.56 million shs

Market Capitalization$13.89 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.64

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

Beat the Market (BTM) Rank^™

2.0 Analyst's Opinion

Consensus Rating
Teva Pharmaceutical Industries has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 6 buy ratings, 14 hold ratings, and 4 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.52, Teva Pharmaceutical Industries has a potential downside of 9.3% from its current price of $12.71.
Amount of Analyst Coverage
Teva Pharmaceutical Industries has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
Teva Pharmaceutical Industries has received 1,277 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Teva Pharmaceutical Industries has received 1,186 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Teva Pharmaceutical Industries has received 51.85% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote “Outperform” if you believe TEVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Teva Pharmaceutical Industries does not currently pay a dividend.
Dividend Growth
Teva Pharmaceutical Industries does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $80,997.00 in company stock.
Percentage Held by Insiders
Only 0.49% of the stock of Teva Pharmaceutical Industries is held by insiders.
Percentage Held by Institutions
48.79% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Teva Pharmaceutical Industries are expected to grow by 7.17% in the coming year, from $2.37 to $2.54 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Teva Pharmaceutical Industries is -16.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Teva Pharmaceutical Industries is -16.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Teva Pharmaceutical Industries has a PEG Ratio of 1.20. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Teva Pharmaceutical Industries has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.38 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:TEVA

Previous Symbol

CUSIPN/A

CIK818686

Webwww.tevapharm.com

Phone972-3914-8171

Debt

Debt-to-Equity Ratio1.68

Current Ratio1.05

Quick Ratio0.70

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio5.36

P/E Growth1.2

Sales & Book Value

Annual Sales$16.89 billion

Price / Sales0.82

Cash Flow$3.81 per share

Price / Cash Flow3.34

Book Value$13.79 per share

Price / Book0.92

Profitability

EPS (Most Recent Fiscal Year)$2.31

Net Income$-998,000,000.00

Net Margins-4.73%

Return on Equity18.10%

Return on Assets4.72%

Miscellaneous

Employees40,039

Outstanding Shares1,092,190,000

Market Cap$13.89 billion

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

How has Teva Pharmaceutical Industries' stock been impacted by COVID-19 (Coronavirus)?

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TEVA shares have increased by 41.1% and is now trading at $12.71. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Teva Pharmaceutical Industries?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 4 sell ratings, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Teva Pharmaceutical Industries.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Teva Pharmaceutical Industries.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced its earnings results on Thursday, May, 7th. The company reported $0.76 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.59 by $0.17. The firm earned $4.36 billion during the quarter, compared to the consensus estimate of $4.15 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.10% and a negative net margin of 4.73%. The business's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the company earned $0.60 EPS. View Teva Pharmaceutical Industries' earnings history.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY20 earnings guidance on Thursday, May, 7th. The company provided EPS guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.44. The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $16.74 billion.

What price target have analysts set for TEVA?

24 brokerages have issued 12 month target prices for Teva Pharmaceutical Industries' stock. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $11.52 in the next twelve months. This suggests that the stock has a possible downside of 9.3%. View analysts' price targets for Teva Pharmaceutical Industries.

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

News coverage about TEVA stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutTeva Pharmaceutical Industries.

Who are some of Teva Pharmaceutical Industries' key competitors?

Some companies that are related to Teva Pharmaceutical Industries include ASTELLAS PHARMA/ADR (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TKPYY), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Beigene (BGNE), GALAPAGOS NV/S (GLPG), Catalent (CTLT) and Sarepta Therapeutics (SRPT). View all competitors.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), NVIDIA (NVDA), AT&T (T), Alibaba Group (BABA), Bank of America (BAC), Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Cisco Systems (CSCO) and Walt Disney (DIS).

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the following people:

Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
Mr. Michael McClellan, Exec. VP & CFO (Age 48)
Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (11.91%), Capital World Investors (3.03%), Menora Mivtachim Holdings LTD. (1.52%), Capital International Investors (1.27%), Phoenix Holdings Ltd. (1.04%) and Harel Insurance Investments & Financial Services Ltd. (0.60%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Sol J Barer and Sven Dethlefs. View institutional ownership trends for Teva Pharmaceutical Industries.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Commerzbank Aktiengesellschaft FI, Sphera Funds Management LTD., Nuveen Asset Management LLC, Capital Research Global Investors, Strs Ohio, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, and Janus Henderson Group PLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, and Richard Daniell. View insider buying and selling activity for Teva Pharmaceutical Industries.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Menora Mivtachim Holdings LTD., Phoenix Holdings Ltd., Noked Capital LTD, Alberta Investment Management Corp, Invesco Ltd., Harel Insurance Investments & Financial Services Ltd., and Beck Mack & Oliver LLC. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Sol J Barer, and Sven Dethlefs. View insider buying and selling activity for Teva Pharmaceutical Industries.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $12.71.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $13.88 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff